Human Bone Marrow Mesenchymal Stem Cells: A Systematic Reappraisal Via the Genostem Experience

Charbord, Pierre; Livne, Erella; Gross, Gerhard; Häupl, Thomas; Neves, Nuno M.; Marie, Pierre; Bianco, Paolo; Jorgensen, Christian
March 2011
Stem Cell Reviews & Reports;Mar2011, Vol. 7 Issue 1, p32
Academic Journal
Genostem (acronym for "Adult mesenchymal stem cells engineering for connective tissue disorders. From the bench to the bed side") has been an European consortium of 30 teams working together on human bone marrow Mesenchymal Stem Cell (MSC) biological properties and repair capacity. Part of Genostem activity has been dedicated to the study of basic issues on undifferentiated MSCs properties and on signalling pathways leading to the differentiation into 3 of the connective tissue lineages, osteoblastic, chondrocytic and tenocytic. We have evidenced that native bone marrow MSCs and stromal cells, forming the niche of hematopoietic stem cells, were the same cellular entity located abluminally from marrow sinus endothelial cells. We have also shown that culture amplified, clonogenic and highly-proliferative MSCs were bona fide stem cells, sharing with other stem cell types the major attributes of self-renewal and of multipotential priming to the lineages to which they can differentiate (osteoblasts, chondrocytes, adipocytes and vascular smooth muscle cells/pericytes). Extensive transcription profiling and in vitro and in vivo assays were applied to identify genes involved in differentiation. Thus we have described novel factors implicated in osteogenesis (FHL2, ITGA5, Fgf18), chondrogenesis (FOXO1A) and tenogenesis (Smad8). Another part of Genostem activity has been devoted to studies of the repair capacity of MSCs in animal models, a prerequisite for future clinical trials. We have developed novel scaffolds (chitosan, pharmacologically active microcarriers) useful for the repair of both bone and cartilage. Finally and most importantly, we have shown that locally implanted MSCs effectively repair bone, cartilage and tendon.


Related Articles

  • Hematopoietic SCT modulates gut inflammation in experimental inflammatory bowel disease. Godoi, D. F.; Cardoso, C. R.; Ferraz, D. B.; Provinciatto, P. R.; Cunha, F. Q.; Silva, J. S.; Voltarelli, J. C. // Bone Marrow Transplantation;Oct2010, Vol. 45 Issue 10, p1562 

    Hematopoietic SCT (HSCT) and high-dose chemotherapy are being explored as therapy for various human refractory immune-mediated conditions, including inflammatory bowel diseases (IBD). Nevertheless, the exact immunological mechanisms by which the BM cells (BMCs) or immunosuppression provide...

  • The effects of low-level laser irradiation on differentiation and proliferation of human bone marrow mesenchymal stem cells into neurons and osteoblasts-an in vitro study. Soleimani, Masoud; Abbasnia, Ehsan; Fathi, Mehdi; Sahraei, Hedayat; Fathi, Yashar; Kaka, Gholamreza // Lasers in Medical Science;Mar2012, Vol. 27 Issue 2, p423 

    Bone marrow-derived mesenchymal stem cells (BMSCs) are promising for use in regenerative medicine. Several studies have shown that low-level laser irradiation (LLLI) could affect the differentiation and proliferation of MSCs. The aim of this study was to examine the influence of LLLI at...

  • Marrow cells offer hope for nerves ravaged by disease. Young, Emma // New Scientist;2/1/2003, Vol. 177 Issue 2380, p18 

    Cites research conducted in Sydney, New South Wales on the potential therapeutic use of bone marrow cells in the treatment of multiple sclerosis (MS). Destruction of nerve insulating protein myelin in patients of MS; Role of myelin in the brain; Differentiation of bone marrow cells into stem...

  • LateTIME: Despite safety, no benefit to bone marrow cell therapy weeks after MI.  // Cardiology Today;Feb2012, Vol. 15 Issue 2, p26 

    The article discusses research study being done on bone marrow cell therapy and myocardial infarction (MI), referencing a study by Jay H. Traverse published in a 2011 issue of the "Journal of the American Medical Association."

  • JAMA: Study examines treatment of heart failure with bone marrow cells.  // Biomedical Market Newsletter;3/28/2012, Vol. 21, p1 

    The article focuses on a study according to which treatment of chronic ischemic heart failure by bone marrow cells of a patient was found ineffective.

  • Stowers scientists successfully expand bone marrow-derived stem cells in culture.  // Biomedical Market Newsletter;9/26/2011, Vol. 21, p620 

    The article reports that researchers from Stowers Institute for Medical Research have successfully expanded bone marrow-derived hematopoietic stem cells in culture which are capable of replenishing and undergoing self-renewal for therapeutic applications.

  • Connecting the Dots: The Promises of Wharton's Jelly Mesenchymal Stem Cells for Tissue Repair and Regeneration. La Rocca, Giampiero // Open Tissue Engineering & Regenerative Medicine Journal;2011, Vol. 4, p3 

    An introduction is presented in which the editor discusses various reports within the issue on topics including the clinical application of Wharton's Jelly mesenchymal stem cells (WJC), the ability of WJC to differentiate towards Schwann cells, and the use of WJC for cardiovascular regeneration.

  • Are cultured mesenchymal stromal cells an option for immunomodulation in transplantation? Plock, Jan A.; Schnider, Jonas T.; Schweizer, Riccardo; Gorantla, Vijay S.; Bondanza, Attilio; Biagi, Ettore // Frontiers in Immunology;Feb2013, Vol. 4, Special section p1 

    The article discusses a study by E. Eggenhofer and colleagues published in an issue of "Frontiers in Immunology" on the role of cultured mesenchymal stromal cells (MSCs) in immunomodulation in transplantation. The researchers presented evidence in a mouse model that cultured bone-marrow derived...

  • Optimization of Targeted Cell Replacement Therapy: A New Approach for Lung Disease. Duchesneau, Pascal; Wong, Amy P.; Waddell, Thomas K. // Molecular Therapy;Oct2010, Vol. 18 Issue 10, p1830 

    Cell replacement therapy is a promising approach for treatment of lung disease such as cystic fibrosis, although rates of engraftment need to be improved. We previously showed improved cell retention in the lung using transtracheal delivery compared to intravenous injection. Here, we optimized...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics